Obesity is characterized by excessive lipid accumulation and chronic inflammation that disrupt metabolic homeostasis. This study investigated the effects of Lactiplantibacillus plantarum GBCCF0227 on lipid metabolism using differentiated 3T3-L1 adipocytes and a high-fat diet (HFD) -induced obese mouse model. In 3T3-L1 adipocytes, exposure to GBCCF0227 culture supernatant was associated with reduced intracellular triglyceride accumulation and lower expression of lipid metabolism-related genes. Consistent with the in vitro observations, oral administration of GBCCF0227 attenuated body weight gain and adipose tissue expansion in HFD-fed mice, together with lower expression of HFD-induced lipid metabolism-related genes (Pparg, Fabp4, Dgat2, and Cs) in white adipose tissue (WAT). GBCCF0227 treatment also reduced the expression of inflammatory markers (Il-6, Il-1b) as well as Leptin, in epididymal WAT. In the liver, GBCCF0227 administration lowered the expression of Pparg and Cd36 and reduced hepatic lipid accumulation. Collectively, these findings indicate that GBCCF0227 administration is associated with coordinated changes in lipid accumulation and lipid metabolism-related gene expression in WAT and liver under HFD conditions. These results highlight the potential of GBCCF0227 as a probiotic candidate for modulating obesity-associated lipid metabolic alterations.
Park et al. (Wed,) studied this question.